Conjonctyl: Reverse Skin Ageing

The hairless rat was used as the model to demonstrate the effect of CONJONCTYL® on the supramolecular arrangement of the extracellular matrix during cutaneous aging

The young non-treated skin of rats 6 months old (control) was compared to that of two other groups of rats aged 17 months. The first group was treated with CONJONCTYL® and the others remained untreated.

The treated rats received at the age of 12 months, a daily topical application of CONJONCTYL®, 5 days a week for 5 months. The results showed that the treatment resulted in collagen fibres and elastin remaining organised. The interfibrillar spaces were maintained and there was a conservation of the dermal thickness. The structural organisation of the treated dermis was very close to that of the 6 month old rats.

A multi-centre clinical study was done to show the effect of CONJONCTYL® on the filling of cutaneous depressions, particularly wrinkles.

Two groups of 50 female volunteers received intra-dermal injections of CONJONCTYL® in 1 to 3 zones of the face (brow wrinkles and crows feet).
The evaluation of results was by means of processing the photos of the skin taken before, and then 3 to 9 weeks after the last injection of CONJONCTYL®. Microphotographs were also taken on the first day of the trial, and repeated 9 weeks after the last injection.

The volunteers evaluated their results by means of an analogue scale.

The skin photos showed a statistically significant improvement in the number and depth of the wrinkles in the brow area.

Parallel to this was an improvement perceived by the volunteers on all the injected sites which remained significant 1 year after the injections for nearly 40% of the volunteers.



This ensemble of experimental and clinical results along with the lasting effects of the treatment adds support to the use of CONJONCTYL® for the reduction of cutaneous depressions, particularly wrinkles.

Conjonctyl is now the only product that is licensed for intradermal application for aesthetic purposes, which has long-lasting benefits for wrinkle reduction and collagen restructuring.

Uses in Aesthetic Medicine:

- Mesolift/Mesoglow
- Acne Scar Reduction (Microneedle Dermaroller)
- Direct injection into wrinkles & depressions

Other injectable fillers have their effects primarily through volume expansion, hence the results only last as long as the fillers themselves. Restylane has some evidence of collagen stimulation, but this is not significant enough to obviate the need for repeat treatments.

Conjonctyl is unique in not being a volume replacing product. It works by assisting the body in creating new collagen of better quality, akin to younger, healthier skin.

The connective tissues are rich in silicon at the time of birth. This reduces with age, owing to poor intestinal absorption of this mineral.

The reduction of silicon content in the skin is partly responsible for the collagen disorganisation seen in ageing skin. This is charaterised by the appearance of cutaneous depressions and loss of elasticity.

Current treatments fill wrinkles and hydrate, but none acts on the actual architecture of cutaneous tissue. Only silicon brought by in-situ injection of Conjonctyl can act as a cutaneous tissue restructurer.

Silicon thus contributes to the integrity of skin.The effectiveness of intradermal organic silicon is particularly obvious in the treatment of wrinkles.

Conjonctyl can be used as a sole agent, or in combination with antioxidants, vitamins and minerals.

Three sessions, a week apart are needed for treatment, followed by the occasional booster.

Conjonctyl has an impressive safety profile with over 24 million bottles sold between 1973-1996.

Patients with Aspirin allergies should not have Conjonctyl.

Conjonctyl is classified as a Class III Medical Device (CE).